Case Report: Respiratory paralysis associated with polymyxin B therapy

Yachan Ning; Yanqi Chu; You Wu; Ying Huang; Chunmei Wang; Li Jiang

doi:10.3389/fphar.2022.963140

Frontiers in Pharmacology (Aug 2022)

Case Report: Respiratory paralysis associated with polymyxin B therapy

Yachan Ning,
Yanqi Chu,
You Wu,
Ying Huang,
Chunmei Wang,
Li Jiang

Affiliations

Yachan Ning: Department of Intensive Care Medicine, Xuanwu Hospital, Capital Medical University, Beijing, China
Yanqi Chu: Department of Pharmacy, Xuanwu Hospital, Capital Medical University, Beijing, China
You Wu: Department of Pharmacy, Xuanwu Hospital, Capital Medical University, Beijing, China
Ying Huang: Department of Urology Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China
Chunmei Wang: Department of Intensive Care Medicine, Xuanwu Hospital, Capital Medical University, Beijing, China
Li Jiang: Department of Intensive Care Medicine, Xuanwu Hospital, Capital Medical University, Beijing, China

DOI: https://doi.org/10.3389/fphar.2022.963140
Journal volume & issue: Vol. 13

Abstract

Read online

Polymyxin B (PMB) and colistin are bactericidal polypeptide antibiotics discovered in 1947 and 1949 for the treatment of gram-negative bacterial infections. Polymyxin was used clinically in the 1950s, but it was gradually replaced by other antibiotics in the 1980s because of its high nephrotoxicity and neurotoxicity. In recent years, the increase of multidrug-resistant negative bacteria has led to the resurgence of polymyxin use. However, its side effects are not clear. Respiratory paralysis caused by PMB-related neuromuscular blockade is a rare but potentially fatal effect. We report a case of respiratory paralysis probably caused by polymyxin B infusion.

Published in Frontiers in Pharmacology

ISSN: 1663-9812 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: http://journal.frontiersin.org/journals/pharmacology

About the journal

Abstract

Keywords